ACTIVITY 2: EXAMINING CANCER PATIENT DATA

Similar documents
2013 Holiday Lectures on Science Medicine in the Genomic Era

OVERVIEW OF CANCER DISCOVERY ACTIVITIES

THE EUKARYOTIC CELL CYCLE AND CANCER

2013 Holiday Lectures on Science Medicine in the Genomic Era

Plasma-Seq conducted with blood from male individuals without cancer.

The Center for PERSONALIZED DIAGNOSTICS

SUPPLEMENTARY INFORMATION

Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope

Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018

IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.

Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins

NeoTYPE Cancer Profiles

Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD

SureSelect Cancer All-In-One Custom and Catalog NGS Assays

Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ

Genomic Medicine: What every pathologist needs to know

Accel-Amplicon Panels

Fluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS

Clinical Grade Genomic Profiling: The Time Has Come

Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester

NeoTYPE Cancer Profiles

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

Jennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA

Genome 371, Autumn 2018 Quiz Section 9: Genetics of Cancer Worksheet

Illumina s Cancer Research Portfolio and Dedicated Workflows

CELL CYCLE REGULATION AND CANCER. Cellular Reproduction II

Next generation histopathological diagnosis for precision medicine in solid cancers

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Section D: The Molecular Biology of Cancer

Secuenciación masiva: papel en la toma de decisiones

Hands-on Activity Viral DNA Integration. Educator Materials

Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities

Out-Patient Billing CPT Codes

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE

Lab title: Cell Division author: Dr. Ruth Dahlquist-Willard (modified by D. Bell)

Insights from Sequencing the Melanoma Exome

Diagnostic test Suggested website label Description Hospitals available

Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory

Got Lactase? The Co-evolution of Genes and Culture

Clinical Grade Biomarkers in the Genomic Era Observations & Challenges

What is the status of the technologies of "precision medicine?

Detecting Oncogenic Mutations in Whole Blood

Biology of cancer development in the GI tract

Ahrim Youn 1,2, Kyung In Kim 2, Raul Rabadan 3,4, Benjamin Tycko 5, Yufeng Shen 3,4,6 and Shuang Wang 1*

Click to edit Master /tle style

Family Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool

Enabling Personalized

LESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2

The benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide

Jocelyn Chapman, MD Division of Gynecologic Oncology. Julie S. Mak, MS, MSc Genetic Counselor Hereditary Cancer Clinic

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

WHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.

Comprehensive Analyses of Circulating Cell- Free Tumor DNA

Genomic landsccape of poorly differentiated and anaplastic thyroid carcinomas: Clues for better classification, risk stratification and therapy

Identifying cancer type speci c oncogenes and tumor suppressors using limited size data

COSMIC - Catalogue of Somatic Mutations in Cancer

The Cancer Genome Atlas Pan-cancer analysis Katherine A. Hoadley

Sample Metrics. Allele Frequency (%) Read Depth Ploidy. Gene CDS Effect Protein Effect. LN Metastasis Tumor Purity Computational Pathology 80% 60%

Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders

Lesson Title: Viruses vs. Cells Standards to be Addressed: Acquisition

Transform genomic data into real-life results

What All of Us Should Know About Cancer and Genetics

August 17, Dear Valued Client:

Cancer genetics

EBUS-TBNA Diagnosis and Staging of Lung Cancer

Precision Genetic Testing in Cancer Treatment and Prognosis

A class of genes that normally suppress cell proliferation. p53 and Rb..ect. suppressor gene products can release cells. hyperproliferation.

Best of ASCO 2014 Sarcoma

EXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)

Nature Genetics: doi: /ng Supplementary Figure 1. Depths and coverages in whole-exome and targeted deep sequencing data.

MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers

New Drug development and Personalized Therapy in The Era of Molecular Medicine

IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY

Corporate Medical Policy

Introduction to Cancer Biology

Tumor suppressor genes D R. S H O S S E I N I - A S L

Precision Oncology: Experience at UW

The mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Changing the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle

Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each

Multistep nature of cancer development. Cancer genes

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Identification of Potential Therapeutic Targets by Molecular and Genomic Profiling of 628 Cases of Uterine Serous Carcinoma

Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies

Name Student Response sheet Period. Cell Division Mitosis Lab

Cancer gene discovery via network analysis of somatic mutation data. Insuk Lee

The preclinical efficacy of a novel telomerase inhibitor, imetelstat, in AML: A randomized trial in patient-derived xenografts

Your World: Fighting Cancer with Biotechnology

Nature Genetics: doi: /ng Supplementary Figure 1

Chapt 15: Molecular Genetics of Cell Cycle and Cancer

Liquid biopsy: the experience of real life case studies

Karyotype analysis reveals transloction of chromosome 22 to 9 in CML chronic myelogenous leukemia has fusion protein Bcr-Abl

Vertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients

Clinical, Pathologic and Molecular Updates

Looking Beyond the Standard-of- Care : The Clinical Trial Option

Cancer Cells. It would take another 20 years and a revolution in the techniques of biological research to answer these questions.

Assessing the Economics of Genomic Medicine. Kenneth Offit, MD MPH Chief, Clinical Genetics Service Memorial Sloan-Kettering Cancer Center

Transcription:

OVERVIEW Refer to the Overview of Cancer Discovery Activities for Key Concepts and Learning Objectives, Curriculum Connections, and Prior Knowledge, as well as background information, references, and additional related resources. MATERIALS Cancer as a Genetic Disease video clip (http://www.hhmi.org/biointeractive/cancer-genetic-disease-videohighlights) Activity 2: Examining Cancer Patient Data student document, which includes the Video Worksheet, (one per student) Set of 32 Cancer Patient Cards, to be distributed one per student. Cut out the cards before class. You may wish to laminate the cards for future use. PROCEDURE This activity consists of the following: A before-class assignment in which students watch a video clip (8:30 minutes) and complete the accompanying Video Worksheet (included in the Activity 2: Examining Cancer Patient Data student document) to learn about the genetic basis of cancer An in-class activity using the Cancer Patient Cards, which involves small-group discussions about the genes involved in different cancers A 3-2-1 analysis assignment, which can be done in class or as homework An optional research project (in the Overview of Cancer Discovery Activities document). Before Class Distribute the Activity2: Examining Cancer Patient Data document to students. Ask them to watch the Cancer as a Genetic Disease video clip and complete the Video Worksheet before class. Note: Some students find the gas pedal and brake analogy confusing (around 2:30 in the film). A mutated oncogene is like putting the foot on the gas pedal, and a mutated tumor suppressor gene is like taking the foot off the brake. Tumor suppressor genes normally act as brakes in the cell cycle. Page 1 of 8

ANSWERS TO VIDEO WORKSHEET 1. What was the main purpose of the large-scale cancer study that Dr. Sawyers describes in the video? The study s aim was to identify the genetic causes of cancer. 2. As of spring 2013, about genes associated with cancer had been identified. What is the approximate breakdown of oncogenes versus tumor suppressor genes? 140 cancer genes; 60 oncogenes and 80 tumor suppressor genes 3. Using Dr. Sawyers analogy (the gas pedal and brake), a mutated oncogene is like and a mutated tumor suppressor gene is like. What does this mean in terms of how the cell grows and divides? A mutated oncogene is like putting the foot on the gas pedal, and a mutated tumor suppressor gene is like taking the foot off the brake. 4. Distinguish between a proto-oncogene and an oncogene. Proto-oncogenes normally stimulate cell growth and division in a carefully controlled way; oncogenes are mutated genes whose protein products cause cells to divide faster. 5. The mutated allele (oncogene) is dominant/recessive compared to the normal, non-mutated allele (protooncogene) on the other chromosome. (Circle a choice.) The mutated allele is dominant. 6. The mutated allele of a tumor suppressor gene is dominant/recessive compared to the normal, nonmutated allele on the other chromosome. (Circle a choice.) The mutated allele of a tumor suppressor gene is recessive. 7. Does Dr. Sawyers think many more cancer genes will be identified? Will the number grow exponentially? More will be identified, but not exponentially more. 8. List the three buckets in which scientists categorize cancer genes. Approximately how many genes are in each bucket? The three buckets are cell growth and survival (~70 genes), cell fate (~60 genes), and gene maintenance (~10 genes). 9. Is p53 a tumor suppressor gene/oncogene? Is cyclin D1 a tumor suppressor gene/oncogene? (Circle a choice.) p53 is a tumor suppressor gene and cyclin D1 is an oncogene. Students may point out that cyclin D1 is actually a proto-oncogene and the mutated form of the gene is an oncogene. 10. How do p53 and cyclin D1 differ in how they affect the cell cycle? p53 limits cell growth and division (brakes), and cyclin D1 stimulates the cell cycle, causing cells to divide. 11. Consider genome maintenance genes: a. Does DNA polymerase make mistakes during DNA replication? Yes b. How often? DNA polymerase makes a mistake about once every billion bases. c. Explain the proofreading system. Enzymes in the cell correct errors in DNA sequence made during DNA replication. d. Explain what happens if a mutation occurs in the genes that encode proofreading enzymes. Without proofreading enzymes, errors would not be corrected and there would be many more mutations in the DNA of cells. 12. Why is it that the longer we live, the more likely we are to develop cancer? Over time, more errors and mutations occur. Page 2 of 8

In Class: Discussion and Cancer Patient Cards Video Discussion As a class, discuss the video clip and address students questions or points of confusion. Suggested discussion questions include the following: What does Dr. Sawyers mean when he says that cancer is a genetic disease? What is the difference between oncogenes and tumor suppressor genes? How do mutations in genes involved in cell growth and survival, cell fate (differentiation), and genome maintenance (or the repair of mistakes in DNA replication) cause cancer? Cancer Patient Cards Activity This activity uses a set of 32 Cancer Patient Cards, each listing the genes mutated in an actual patient s cancer. The data displayed on the cards were obtained from the Catalogue of Somatic Mutations in Cancer (COSMIC) database and information provided in a study by Vogelstein et al. (see references in the overview document). The cancers fall into eight types defined by the organ or tissue they affect lung cancer, breast cancer, colorectal cancer, glioma (brain), melanoma (skin), hepatic cancer (liver), pancreatic cancer, and leukemia (blood) with four different patients per cancer type. The DNA from each patient s tumor was sequenced to identify all the mutations present. Only mutations known to drive the development of cancer, according to Vogelstein et al., are listed on the cancer cards. Each card (Figure 3) contains the cancer type, the patient number, the genes mutated in that particular patient, the chromosome location of each gene, the gene classification (oncogene or tumor suppressor), and the cellular process that gene affects (cell survival, cell fate, or genome maintenance). Altogether the cards list 51 different genes (Table 1). Figure 3. Example of a Cancer Patient Card. Abbreviations: TS, tumor suppressor; O, oncogene; CS, cell survival; and CF, cell fate. Page 3 of 8

Table 1. List of Cancer Patient Cards. There are four cards per cancer type, each card representing a different patient sample. In total, 51 genes are associated with the cancers listed on the 32 cards. Cancer Type Sample Genes 1 NF1 SETBP1 TP53 Lung cancer Breast cancer Colorectal cancer Glioma Melanoma Hepatic cancer Pancreatic cancer Leukemia 2 EGFR MLL2 3 CTNNB1 KRAS NF2 TP53 4 KT MEN1 MLL3 TP53 1 BRCA1 TP53 2 CDH1 PIK3CA 3 ARID1B TP53 4 FGFR2 GATA3 1 APC TP53 2 KDM6A KRAS PIK3CA SMAD4 3 APC ATM 4 BRAF CARD11 GNAS PIK3CA SMAD4 TP53 1 CIC IDH1 PIK3C5 2 CBL TP53 3 ALK ATM BRCA1 TP53 4 HNF1A PTEN 1 BRAF CREBBP EP300 2 FGFR2 MLL3 NRAS PTCH1 3 BRAF APC BCOR JAK3 MLL2 4 BRAF CDKN2A MLL3 ATM PAX5 1 ARID1A ARID2 BRCA1 RB1 TP53 2 CTNNB1 MED12 3 HNF1A TP53 4 ARID2 AXIN1 JAK2 TP53 1 APC GNAS KRAS RNF43 2 KRAS TRAF7 TP53 3 CDKN2A KRAS MPL TP53 4 KRAS SMAD4 TP53 1 MYD88 SETD2 2 BCOR NOTCH1 3 BRAF FAM123B KRAS 4 NOTCH1 PIK3CA TP53 Note: TP53 is the gene that encodes the tumor suppressor p53. BRCA1 is a gene involved in familial cases of breast cancer. Some of these genes have multiple names. For example, FAM123B is also called AMER1; MLL2 is also called KMT2D, and MLL3 is also called KMT2C. Page 4 of 8

1. Distribute the cards. There are 32 Cancer Patient Cards; distribute one card to each student in the class. Briefly explain the information found on each card. Note that each card describes the driver genetic mutations found in a cancer from one person. The 32 cards reflect 32 different patients cancers. You may wish to write the cancer card legend on the board to remind students of the definitions of the acronyms TS, O, CF, CS, and GM. 2. Form small groups based on cancer type. Ask the students to form small groups based on their cancer types. Students should locate other students in the class with the same cancer type on their cards. All the lung cancers should be together, all the breast cancers, and so on. Allow students 15 minutes to compare cards and to identify and record patterns or trends they observe as they study the information on the cards. They should record their observations in their notebooks. Students may make the following observations: The genes are located on many different chromosomes. Different combinations of the mutated genes can cause tumors of the same cancer type. A different number of genes can be involved in the same type of cancer. Some genes are more common than others in the same type of cancer (i.e., TP53 is on three of the four lung cancer cards; BRAF is on three of four skin cancer cards). 3. Form small groups based on patient number. After 15 minutes, ask students to form groups based on their sample numbers. Students should locate other students in the class who have the same patient number (i.e., all the cards with a 1 together; for example, LC1, BC1, CC1, L1, etc.). This time each group consists of different cancer types. Students will have 10 minutes to identify and record any new patterns or trends that they did not identify when they were in their cancertype groups. Remind students that each card represents a different patient. Students may make the following observations: Mutations in the same genes (i.e., TP53, KRAS, BRAF) have been identified in different types of cancer. Different driver mutations affect genes that are on the same chromosome but are involved in different types of cancer. Few driver mutations are in genes involved in genome maintenance. Whole Class Activity and Discussion 1. Construct a cancer genes table. Construct a cancer genes table as a class either on the board or using the template provided in Table 2. Ask each student to read aloud the names of the genes on his or her card and keep a tally on the table of how many times a gene name is called out. You may also note the type of cancer each gene is associated with or whether the gene is a tumor suppressor gene or an oncogene. By creating this table, students will see an overall picture of the genes mutated in different cancer types, which will be different from what they observed in their small groups. Page 5 of 8

Table 2. Cancer Gene Table Template. Use this template to build a cancer gene table by asking each student to read aloud the mutations on their Cancer Patient Cards and record the number of times a particular gene is called out. Note the type of cancer associated with a mutation. The 51 cancer genes are listed alphabetically in the sample table below. Gene Cancer Type(s) Tally ALK APC ARID1A ARID1B ARID2 ATM AXIN1 BCOR BRAF BRCA1 CARD11 CBL CDH1 CDKN2A CIC CREBBP CTNNB1 EGFR EP300 FAM123B FGFR2 GATA3 GNAS HNF1A IDH1 JAK2 JAK3 KDM6A KIT KRAS MED12 MEN1 MLL2 MLL3 MPL MYD88 NF1 NF2 NOTCH1 NRAS PAX5 PIK3CA PTCH1 PTEN Page 6 of 8

RB1 RNF43 SETBP1 SETD2 SMAD4 TP53 TRAF7 2. Lead a class discussion. Ask students to make observations from the table and from their own small-group discussions. Students may make the following observations: Fifty-one different genes are mutated in these cancers. Cancers of the same type don t have the same combinations of mutated genes. Certain genes are involved in multiple types of cancer. Some genes are mutated more frequently than other genes. There are 19 oncogenes and 32 tumor suppressor genes. Twenty-four of the genes influence cell fate, 23 influence cell survival, two influence both cell fate and cell survival, and two influence genome maintenance. Assign a 3-2-1 analysis. Assign students a 3-2-1 analysis for the activity either individually or in small groups. The analysis should include three things the student learned from the activity, two things that surprised or particularly interested them, and one question they still have. If students are assigned to do the analysis individually, they can complete it either in class or as homework. A grading rubric for this analysis can be found in the Overview document. TEACHING TIPS If students need a refresher on the cell cycle, consider using The Eukaryotic Cell Cycle and Cancer Click and Learn before doing this activity. The p53 Gene and Cancer Click and Learn can also be helpful. Depending on the number of students in the class, you can adjust the number of cancer cards distributed. For example, if you have 21 students, you could use seven of the eight cancer types and three of the four patient groups (i.e., 7 3 = 21 cards). Try to make sure that you distribute an equal number of patientnumber cards for each cancer type. Rotate among the groups as students work and, if necessary, ask them to consider the following questions: Are any genes in common among your patients? Are all the genes on the same or different chromosomes? How many oncogenes versus tumor suppressor genes are there? You might prompt them to make a list of the genes mutated in multiple cancers versus genes that were only mutated in a single type of cancer. Point out to students that these genes represent only a subset of all genes known to be involved in cancer. Researchers have so far identified about 140 genes involved in cancer. About 80 are tumor Page 7 of 8

suppressor genes and about 60 are oncogenes. For an activity that illustrates all of the cancer-causing genes, see Activity 1: Classifying Cancer Genes. SOCIAL MEDIA SUGGESTIONS The cancer gene table could be assembled using a pre-prepared Google Docs spreadsheet. Students add their data to the spreadsheet, and the whole class can see it build collectively. If the tally column is built as a formula, it will grow as the students enter their data. You could draw an analogy between the collaborative, online building of a data set accomplished by the students and the genome analysis done by the researchers (on a larger scale). Students could post their 3-2-1 analyses as blog posts (on a class blog or individual student blogs). Once posted, the comments feature could be used to facilitate peer review. With the suggested rubric, students could be assigned to review their own blog post plus those of two other students. As an alternative optional extension project, students could create a genetics of cancer infographic, intended for patient education at an oncologist s office. Free, online infographic creation tools (such as Easel.ly or Picktochart) are available. AUTHORS This activity was written by Ann Brokaw, Rocky River High School, Rocky River, OH, Laura Bonetta, PhD, and Eriko Clements, PhD, HHMI. The Cancer Patient Cards were developed by Travis Dittmer, Ph.D. Edited by Laura Bonetta, PhD, HHMI, Robin Heyden, consultant and Susan Dodge, consultant; copyedited by Barbara Resch and Linda Felaco. Reviewed by Nancy Staub, P.D, Gonzaga University, WA, and David McDonald, PhD, North Carolina Central University. FIELD TESTERS Caitlin Ullock, Melissa Csikari, Helen Snodgrass, Beth Pethel, Robin Cochran Dirksen, Sarah Freilich Page 8 of 8